Description:
This active molecular is an α2δ-1 ligand being developed for pain associated with diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia which related to related to drugs such as gabapentin and pregabalin. Mirogabalin binds to the α2δ calcium channels (1 and 2) and was estimated to be much more potent than pregabalin. In Nov 2015, a Japanese company named Daiichi Sankyo plans a phase III trial for Postherpetic neuralgia and Neuropathic pain (in patients with diabetic peripheral neuropathy and renal impairment) in Japan . In May 2016, Pharmacokinetics and adverse data from a phase I trial in volunteers presented at the 35th Annual Scientific Meeting of the American Pain Society .
- Molecular Weight:209.29
- Purity:98%
Molecular Formula:
C12H19NO2
Canonical SMILES:
CCC1=CC2C(C1)CC2(CC(=O)O)CN
InChI:
InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1
InChIKey:
FTBQORVNHOIASH-CKYFFXLPSA-N
Solubility:
Soluble in DMSO
Appearance:
powder
Application:
treatment of diabetic peripheral neuropathic pain
Storage: -20°C Freezer
Synonyms:
2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid, DS-5565,CAS#1138245-21-2 ( Mirogabalin besylate); Más detalles se encuentran
aquí